Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

Abstract Background The IMpassion130 trial demonstrated that adding atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel improved the survival of patients with untreated, advanced, programmed death ligand 1 (PDL1)-positive triple-negative breast cancer (TNBC). In view of the high cost of immu...

Full description

Bibliographic Details
Main Authors: Lee Cheng Phua, Soo Chin Lee, Kwong Ng, Mohamed Ismail Abdul Aziz
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Health Services Research
Subjects:
Atezolizumab
Immunotherapy
Programmed death ligand-1
Triple-negative breast cancer
Cost-effectiveness
Partitioned-survival
Online Access:http://link.springer.com/article/10.1186/s12913-020-05445-6

Internet

http://link.springer.com/article/10.1186/s12913-020-05445-6

Similar Items